295 related articles for article (PubMed ID: 8006339)
1. Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.
Blanco C; Lucas T; Alcañiz J; Davila N; Serrano P; Barcelò B; Estrada J
J Endocrinol Invest; 1994 Feb; 17(2):99-104. PubMed ID: 8006339
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.
Kwekkeboom DJ; de Jong FH; Lamberts SW
J Clin Endocrinol Metab; 1989 Jun; 68(6):1128-35. PubMed ID: 2542356
[TBL] [Abstract][Full Text] [Related]
3. Resolution of possible paradoxical responses of gonadotropins to thyrotropin-releasing hormone with bromocriptine therapy in a patient with follicle-stimulating hormone-secreting pituitary adenoma.
Mercado-Asis LB; Yasuda K; Ishizawa M; Ishizuka T; Murayama M; Shimokawa K; Miura K
Endocrinol Jpn; 1992 Aug; 39(4):401-6. PubMed ID: 1446655
[TBL] [Abstract][Full Text] [Related]
4. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
5. The effect of thyrotropin-releasing hormone on gonadotropin and free alpha-subunit secretion in patients with acromegaly and functionless pituitary tumors.
Popovic V; Damjanovic S
Thyroid; 1998 Oct; 8(10):935-9. PubMed ID: 9827662
[TBL] [Abstract][Full Text] [Related]
6. The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro.
Lamberts SW; Verleun T; Oosterom R; Hofland L; van Ginkel LA; Loeber JG; van Vroonhoven CC; Stefanko SZ; de Jong FH
J Clin Endocrinol Metab; 1987 Mar; 64(3):524-30. PubMed ID: 3102540
[TBL] [Abstract][Full Text] [Related]
7. Reduction of plasma gonadotropin levels and pituitary tumor size by treatment with bromocriptine in a patient with gonadotropinoma.
Yamakita N; Komaki T; Murai T; Kawamura S
Intern Med; 1999 Mar; 38(3):266-71. PubMed ID: 10337939
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.
Sassolas G; Lejeune H; Trouillas J; Forest MG; Claustrat B; Lahlou N; Loras B
J Clin Endocrinol Metab; 1988 Jul; 67(1):180-5. PubMed ID: 2967850
[TBL] [Abstract][Full Text] [Related]
10. Recognition of gonadotroph adenomas in women.
Daneshdoost L; Gennarelli TA; Bashey HM; Savino PJ; Sergott RC; Bosley TM; Snyder PJ
N Engl J Med; 1991 Feb; 324(9):589-94. PubMed ID: 1899470
[TBL] [Abstract][Full Text] [Related]
11. Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine.
Berezin M; Olchovsky D; Pines A; Tadmor R; Lunenfeld B
J Clin Endocrinol Metab; 1984 Dec; 59(6):1220-3. PubMed ID: 6436289
[TBL] [Abstract][Full Text] [Related]
12. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
[TBL] [Abstract][Full Text] [Related]
13. Abnormal response of luteinizing hormone beta subunit to thyrotrophin-releasing hormone in patients with non-functioning pituitary adenoma.
Gil-del-Alamo P; Pettersson KS; Saccomanno K; Spada A; Faglia G; Beck-Peccoz P
Clin Endocrinol (Oxf); 1994 Nov; 41(5):661-6. PubMed ID: 7828356
[TBL] [Abstract][Full Text] [Related]
14. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
[TBL] [Abstract][Full Text] [Related]
15. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
16. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone.
Daneshdoost L; Gennarelli TA; Bashey HM; Savino PJ; Sergott RC; Bosley TM; Snyder PJ
J Clin Endocrinol Metab; 1993 Nov; 77(5):1352-5. PubMed ID: 8077332
[TBL] [Abstract][Full Text] [Related]
17. Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201-995).
Sassolas G; Serusclat P; Claustrat B; Trouillas J; Merabet S; Cohen R; Souquet JC
Horm Res; 1988; 29(2-3):124-8. PubMed ID: 2456975
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.
Abs R; Parizel PM; Beckers A
J Endocrinol Invest; 1991 Feb; 14(2):135-8. PubMed ID: 1905737
[TBL] [Abstract][Full Text] [Related]
19. Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.
Chanson P; Lahlou N; Warnet A; Roger M; Sassolas G; Lubetzi J; Schaison G; Bouchard P
J Endocrinol Invest; 1994 Feb; 17(2):91-8. PubMed ID: 8006338
[TBL] [Abstract][Full Text] [Related]
20. Response of luteinizing hormone secreting pituitary adenoma to a long-acting somatostatin analogue.
Vos P; Croughs RJ; Thijssen JH; van 't Verlaat JW; van Ginkel LA
Acta Endocrinol (Copenh); 1988 Aug; 118(4):587-90. PubMed ID: 2899940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
